Nonprofit blood bank hosting blood drives throughout Mid-South
A nonprofit blood bank is searching for blood donors and needs the community’s help in saving lives.
UTHSC In the Media
Erlanger Health System Achieves Strong Results in Robotic Access and OR Capacity with Qventus, On Track to Deliver 5x Annualized ROI
Qventus’ Surgical Growth Solution secured 220 additional surgical cases per month, achieving break-even across all sites in less than three months
Erlanger Health System Achieves Strong Results in Robotic Access and OR Capacity with Qventus, On Track to Deliver 5x Annualized ROI
Qventus, the industry’s leading provider of AI-based care operations automation software, today announced strong results from its partnership with Erlanger, a nationally-acclaimed, multi-hospital health system.
McCoy named assistant dean of HCOP Mobile Campus
Following an internal search, Dr. Emily McCoy, associate clinical professor in the Department of Pharmacy Practice, has been named Assistant Dean of the Harrison College of Pharmacy’s Mobile Campus.
A stable for the Sheriff’s Office mounted-patrol unit. A bomb-squad robot. A new county medical examiner.
The Shelby County Board of Commissioners votes Monday, Feb. 2, on Dr. Scott Collier’s appointment by County Mayor Lee Harris as Shelby County medical examiner.
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA)… Read More
FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic Reactions
The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA)… Read More